Avelo Airlines to End DHS Deportation Flights and Close Arizona Base Amid Rising Costs 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
Hyundai Motor Shares Surge on Nvidia Partnership Speculation 
Discord Confidentially Files for U.S. IPO, Signaling Major Milestone 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Barclays Invests in Stablecoin Clearing Firm Ubyx to Advance Digital Money Strategy 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Newmont Goldcorp Expects Lower Q1 2026 Gold Output After Western Australia Bushfire 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
MORRISTOWN, N.J., April 05, 2016 -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today that Doug Drysdale, Chairman and Chief Executive Officer, and Sanjay Patel, Chief Financial Officer, will present at Needham & Company’s 15th Annual Healthcare Conference, as follows.
| Date: | Wednesday, April 13, 2016 | |
| Time: | 3:00 PM EDT | |
| Location: | New York, NY - Westin New York Grand Central Hotel | |
About Pernix Therapeutics
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and pain management, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its Pernix sales force and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.
To learn more about Pernix Therapeutics, visit www.pernixtx.com.
Investor Relations Sanjay Patel, (800) 793-2145 ext. 1009 Chief Financial Officer [email protected] Matthew P. Duffy, 212.915.0685 LifeSci Advisors, LLC [email protected]
